Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content

06 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/06/3268403/0/en/Scienture-Provides-Annual-Shareholder-Update-Outlining-Significant-Progress-and-Strategic-Priorities-for-the-Year-Ahead.html

30 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/30/3264594/0/en/SCIENTURE-Reports-Year-End-2025-Financial-Results-and-Provides-Business-Update.html

11 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/11/3253734/0/en/SCIENTURE-Broadens-Commercial-Access-for-REZENOPY-Highest-Dose-FDA-Approved-Naloxone-Nasal-Spray-Through-GPO-Agreements-Reaching-Over-5-000-U-S-Institutions.html

03 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/03/3231048/0/en/SCIENTURE-Provides-Commercial-Update-on-ARBLI-the-First-FDA-Approved-Ready-to-Use-Oral-Suspension-of-Losartan-Potassium.html

14 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/14/3218585/0/en/SCIENTURE-Announces-Issuance-of-Orange-Book-Listable-Patent-Covering-REZENOPY-the-Highest-Dosage-Naloxone-HCl-Nasal-Spray-Approved-by-the-FDA-for-Life-Saving-Opioid-Overdose-Emerge.html

10 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/10/3203129/0/en/SCIENTURE-and-BlinkRx-Announce-Strategic-Collaboration-to-Expand-Patient-Access-to-Arbli-the-First-FDA-Approved-Ready-to-Use-Oral-Suspension-of-Losartan-Potassium.html
ABOUT THIS PAGE